[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659920":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":21,"studyPopulation":22,"armGroups":23,"interventions":18,"overallOfficials":26,"centralContacts":34,"locations":43,"responsibleParty":67,"collaborators":69,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":18,"enrollmentInfo":86,"targetDuration":18,"studyType":89,"phases":18,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":97,"whyStopped":18,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Royal Marsden NHS Foundation Trust","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Prevalence, method of diagnosis, stage at diagnosis, outcomes of prostate cancer in the Oxleas NHS prison population","Prevalence statistics from the number of adult men and people with prostates in the prison population under Oxleas NHS Foundation Trust, who are identified as living with a diagnosis of prostate cancer. For those who received the diagnosis in prison, data will be collected form their electronic health record to include PSA at diagnosis, method of diagnosis (diagnosed through PSA screening, symptomatic presentation via primary care\u002F2-week-wait referral, emergency presentation), stage and grade at diagnosis and time intervals between referral and diagnosis and treatment received.","Electronic health records will be searched from the earliest available to completion of data extraction, anticipated 31 July 2027. Data collection will occur between January 2027 and July 2027.",[14],{"measure":15,"description":16,"timeFrame":17},"How does the primary outcome data compare to the general population included in the UKGPCS dataset","Comparison between prostate cancer diagnosis, treatment and outcome data collected from the prison population with age and ethnicity matched individuals in the general population from the UKGPCS dataset, using statistical analysis to present findings.","Comparison between data sets and statistical analysis will occur in July and August 2027.",null,{"allocation":18,"interventionModel":18,"interventionModelDescription":18,"primaryPurpose":18,"observationalModel":6,"timePerspective":20,"maskingInfo":18},"RETROSPECTIVE","This study aims to test and develop data collection processes for System One electronic healthcare records at Oxleas NHS Foundation Trust. To use these data collection methods to determine how many people are living with prostate cancer in prison, how prisoners are diagnosed with prostate cancer while in prison, whether they are diagnosed with early or late-stage disease and what are their treatment and survival outcomes.\n\nWe will note all cases of individuals living with prostate cancer in the Oxleas prison population.\n\nWe will investigate the parameters below for those diagnosed with prostate cancer during their sentence in the Oxleas prison population, as far back as electronic health records allow:\n\n* Age at diagnosis\n* Symptomatic at diagnosis\n* Mode of detection (emergency admission, GP\u002Fprimary care, PSA screening)\n* PSA at diagnosis\n* Prostate cancer stage at diagnosis (TMN)\n* Gleason score at diagnosis\n* MDT treatment recommendation (curative or non-curative)\n* Treatment modality (AS, RT, Surgery, SACT \\[Chemo, Hormone therapy, immunotherapy\\], palliative\u002F best supportive care, no treatment, other) offered at MDT\n* Treatment modality (AS, RT, Surgery, SACT \\[Chemo, Hormone Hormone therapy, immunotherapy\\], palliative\u002F best supportive care, no treatment, other) chosen by patient\n* Time until progression (in five-year age bands of year of diagnosis to cover things like reclassification and change in treatment regimens)\n* Five-year survival\n* Cause of death\n\nWe will also assess for other markers of poor access to cancer screening, delayed diagnosis and aggressive disease, such as:\n\n* Pathology - prostate cancer grade and histology at diagnosis\n* Time elapsed from date referral received to date patient notified of diagnosis (NG12 suspected cancer pathway referral states this should be within 28 days(18))\n* Time elapsed from referral and receiving first treatment\n* Number of appointments cancelled or marked 'Did Not Attend' These data will provide novel evidence regarding prostate cancer diagnosis and treatment in prisoners under the care of NHS prisons.\n\nPhase Two; Secondary objective\n\nHow do the prevalence, PSA at diagnosis, method of diagnosis and treatment outcomes for men diagnosed with prostate cancer while in prison compare to that in the general population? To assess this, the data sets from Phase One will be compared with a general population group, using data from the UK Genetic Prostate Cancer Study (UKGPCS) to represent general population data, which will allow us to adjust for age and ethnicity as appropriate.\n\nThe UKGPCS was established in 1993 and is the largest prostate cancer study in the UK, with data from 16,000 prostate cancer patients. The study is based with this same research team at the ICR and RMH. Participants in UKGPCS are patients diagnosed with prostate cancer and who have consented to genetic testing and the storage of data detailing their diagnosis (including the above parameters that we wish to extract for our prison population) and the future use of their data by the ICR research team. The control group will be the systematic series collection of data from The Royal Marsden clinics in the UKGPCS data set.\n\nOne limitation of this study is that the UKGPCS dataset we are using for comparison may include self-selection bias and the 'healthy worker effect', as well as not being representative of the general population in terms of area and ethnicity.","Men diagnosed with prostate cancer while in the care of His Majesty's Prison Service, are less likely to be diagnosed from screening and more likely to be diagnosed with late-stage disease, compared to that in the general population. In addition they are at risk of less favourable outcomes in terms of curative treatment and survival, compared to the general population.",[24],{"label":25,"type":18,"description":18,"interventionNames":18},"N\u002FA data collection of pre-existing data from 9007 adult male prisoners",[27,30],{"name":28,"affiliation":5,"role":29},"Dr Elizabeth Bancroft","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":32,"role":33},"Dr Rose Hall","Institute of Cancer Research, United Kingdom","STUDY_CHAIR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":18,"email":38},"CONTACT","+44 (0)20 8722 4483","rose.hall@icr.ac.uk",{"name":40,"role":36,"phone":41,"phoneExt":18,"email":42},"Dr Joanne Droney","02078082761","joanne.droney@rmh.nhs.uk",[44],{"facility":45,"status":18,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"The Royal Marsden NHS Foundation Trust","Sutton","Surrey","SM2 5PT","United Kingdom","UK",{"type":52,"coordinates":53},"Point",[54,55],-0.2,51.35,{"lat":55,"lon":54},[58,59,60,63,64,66],{"name":31,"role":36,"phone":37,"phoneExt":18,"email":38},{"name":40,"role":36,"phone":41,"phoneExt":18,"email":42},{"name":61,"role":62,"phone":18,"phoneExt":18,"email":18},"Professor Andrew Forrester","SUB_INVESTIGATOR",{"name":40,"role":62,"phone":18,"phoneExt":18,"email":18},{"name":65,"role":62,"phone":18,"phoneExt":18,"email":18},"Dr Alex Bunn",{"name":28,"role":29,"phone":18,"phoneExt":18,"email":18},{"type":68,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[70,73],{"name":71,"class":72},"Public Health England","OTHER_GOV",{"name":74,"class":75},"The Institute of Cancer Research, Sutton, Surrey, UK","UNKNOWN","100659920","prostate-cancer-in-uk-prisons-a-retrospective-data-analysis-100659920",false,"NCT07870707","Prostate Cancer in UK Prisons: A Retrospective Data Analysis","Prostate Cancer Retrospective Prevalence, Screening, Outcome Data in NHS-served Prisons UK (PRISON-UK)","PRISON-UK","Inclusion Criteria\n\nPseudo-anonymous data from prostate cancer code-search in the digital health records of:\n\n* Adult men (over 18 years of age) and people with prostates in the UK prison population with healthcare under Oxleas NHS Trust (sample includes 13 prisons under Oxleas NHS Trust with 9,007 adult men).\n* Full data extraction will only occur for prisoners who have been diagnosed with prostate cancer while in the custody of His Majesty's Prison Service. The number of prisoners living with a diagnosis of prostate cancer will be noted, but no further data extraction will take place if diagnosed outside of prison.\n* Prostate cancer diagnosis may be made clinically (based on symptoms, PSA levels and clinical examination) or confirmed with histology. Core data that ideally should be available for inclusion are:\n\n  * age at diagnosis\n  * method of diagnosis (screening\u002F 2WR (symptomatic)\u002F emergency),\n  * PSA at diagnosis\n  * prostate cancer stage at diagnosis.\n* The prisoners may or may not have another primary cancer at time of diagnosis, however the prostate cancer itself must also be a prostate primary.\n\nRecords will be searched as far back as the Oxleas Data Team will be able to search electronic health records.\n\nExclusion criteria\n\n* Although the number of prisoners living with a diagnosis of prostate cancer will be noted, those who were diagnosed with prostate cancer outside of their prison stay will not undergo further data extraction for data around diagnosis and outcomes.\n* Potential participants who have opted out via the NHS England National Data Opt-Out (NDOO) service and therefore their data will not be used.\n\nIndividual cases will be excluded if it is found that a diagnosis of prostate cancer was not received, even if they underwent extensive investigations for prostate cancer.","MALE","18 Years",{"count":87,"type":88},9007,"ESTIMATED","OBSERVATIONAL","Prostate cancer is the most common cancer affecting men in the UK and is the most common cancer in UK prisons.\n\nEarly diagnosis is vital because treatment is more effective when the disease is detected at an early stage. However, people in prison face significant barriers to healthcare, and little is known about how prostate cancer affects this population. This is concerning, as the prison population is ageing, and men over 50 are at the highest risk of developing prostate cancer.\n\nResearch shows that prisoners are more likely to be diagnosed with any cancer at a late stage, often through emergency hospital visits, and are less likely to receive timely or curative treatment compared to the general population. Survival rates are also worse. However, there are very little data from the UK describing prostate cancer diagnosis and outcomes in the UK from the prison population, which is why we want to find out information about prostate cancer diagnosis in prisons compared to in the general population.\n\nThis project, a collaboration between Oxleas NHS Trust and The Royal Marsden, will test and develop processes for extracting pseudo-anonymised data from the prison population. Using pseudo-anonymous data from prisoner health records in Oxleas NHS Trust, we will assess prevalence and examine how prostate cancer is diagnosed, the treatments offered, and the survival outcomes. We will compare these results against UK Genetic Prostate Cancer Study (UKGPCS) data about men of a similar age in the general population. Our aim is to understand whether prisoners face delays in diagnosis and worse outcomes, and to assess whether prison-based screening could help.\n\nThe findings will inform future healthcare research and the development of policies and may support the development of tailored educational resources and screening approaches, ultimately helping to reduce health inequalities and improve outcomes for people in prison.",[92],"Prostate Cancer",[94,95,96],"Prisoner health","Prostate cancer early diagnosis","Prostate cancer screening","NOT_YET_RECRUITING","2026-10-06",{"date":100,"type":101},"2026-10-13","ACTUAL",{"date":103,"type":88},"2026-12-03",{"date":105,"type":88},"2028-08-03",{"name":5,"class":6},1]